Dr. Andrew J. Dannenberg

• 
  www.alliancerr.com/Resources/Article-Detail.aspx?aid=60 - [Cached Version]
  Published on: 10/12/2008    Last Visited: 3/2/2008  

  Finding ways to interrupt this pathway in a manner that causes few side effects is the ultimate goal of this research,, explains the study's senior author Dr. Andrew Dannenberg, director of the newly established Cancer Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and the Henry R. Erle, M.D.-Roberts Family Professor of Medicine at Weill Cornell Medical College.
  ...
  In 2006, researchers led by Dr. Dannenberg discovered that cyclooxygenase (COX) protein-derived prostaglandin E2 (PGE2) could turn on the gene that expresses aromatase.More recently, the healthy form of the BRCA1 tumor-suppressor gene was found to quiet the aromatase gene -- performing its duty in keeping breast cancer risk low.
  
  ,Maintaining this BRCA1-aromatase relationship in a healthy balance may help to keep patients free of hormone-dependent breast cancer,, Dr. Dannenberg explains.
  
  Studies have shown that use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) can also dampen PGE2 production and aromatase activity.COX-2 inhibitors (which include Vioxx and Celebrex) may do the same.However, these drugs also suppress a prostanoid that helps protect the heart, and in 2004 Vioxx was withdrawn from the market due to an excess of cardiovascular events noted in long-term users.
  
  ,So, we are always looking for other points in the prostaglandin -- aromatase -- estrogen pathway that can shield women from breast cancer without raising risks in other areas,, Dr. Dannenberg says.
  
  That's one of the reasons the results of the new study are intriguing.
  ...
  First of all, it adds valuable new information to the study of hormone-dependent breast cancer generally. ,Pinpointing the role of these receptors is like adding two important new parts to the tumor's 'instruction kit.' You have to understand all the players involved if you hope to uncover weaknesses to fight or prevent the disease,, Dr. Dannenberg says.

• 
  www.scprostate.org/news_archive/2005_03.htm - [Cached Version]
  Published on: 3/1/2005    Last Visited: 6/22/2007  

  "It is well established that COX-2 is a significant and rational target for anti-cancer therapy," said Andrew Dannenberg, M.D., director of cancer prevention at the Weill Medical College of Cornell University and senior author of the paper.
  
  "These studies suggest that celecoxib exerts a second mode of action independent of its known anti-inflammatory mechanism that imposes further restrictions on the proliferation of prostate cancer cells.The results provide potentially important insights into our understanding of the overall anti-tumor activity of selective COX-2 inhibitors."
  
  Dannenberg and a team of investigators discovered this new mechanism by applying celecoxib to prostate cancer cells that failed to express COX-2.Here, the scientists observed that the celecoxib-treated cancer cells did not replicate as rapidly as untreated cells.After further analysis, they found the drug worked by suppressing amounts of cyclin D1, a protein that's essential if cells are to grow, divide and spread.The scientists also attempted to replicate the experiment with Vioxx substituting for celecoxib.In this case, the prostate cancer cells continued to flourish.
  
  "These results support the notion of a unique action by celecoxib that is independent of COX-2, and that's different from Vioxx," said Dannenberg.
  
  "These beneficial effects were observed at concentrations of celecoxib that occur in humans," added Dannenberg."This increases the likelihood that our findings are clinically relevant."
  
  Dannenberg and his colleagues then demonstrated that celecoxib worked in animals that served as hosts for human prostate tumors.In this animal model, celecoxib not only was shown to reduce proliferation of cancer cells, but also reduced the growth of blood vessels at the tumor sites.As a result, tumor mass and blood vessel density in the treated animals was about half that observed in the untreated animals.
  
  Contributing to the studies, along with Dannenberg, were Kotha Subbaramaiah, Baoheng Du and Mindy Chang from Weill Medical College of Cornell University, New York, N.Y.; Manish Patel, Carlos Cardon-Cardo, and Howard Thaler, Memorial Sloan-Kettering Cancer Center, New York, N.Y.; and Peiying Yang and Robert Newman, UT M.D.

• 
  lefcms.lef.org/news/LefDailyNews.htm?NewsID=6207&Sectio - [Cached Version]
  Published on: 10/12/2008    Last Visited: 12/26/2007  

  Dr. Andrew Dannenberg, director of the Cancer Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in Manhattan, estimates that pathogens underlie anywhere from 15 to 20 percent of cancers affecting people globally.
  
  "The magnitude of that link is grossly underappreciated," Dannenberg said of viruses, bacteria and parasites that trigger tumor development.
  ...
  Dannenberg chaired the scientific program committee for the sixth annual meeting on cancer prevention sponsored by the American Association for Cancer Research, which met last week in Philadelphia.It was there that he called on the medical community to increase its efforts to combat infections through improved vaccines and new anti-infectives.
  
  Many of the infectious agents that can cause cancer are more problematic in poorer countries where vaccine technology is nonexistent and costs to purchase from abroad prohibitive.
  
  The World Health Organization has underscored that the lack of money and poor refrigeration capacities in many underdeveloped countries makes access to the HPV vaccine difficult.
  
  "There are about 450,000 new cases of cervical cancer each year worldwide, and more than 200,000 deaths," Dannenberg said.
  ...
  If a significant number of lives are to be saved we need one that doesn't require refrigeration," Dannenberg said.
  
  "Currently, you have to give three vaccinations," for the HPV vaccine to be complete, he added.
  ...
  Dannenberg, meanwhile, said the estimate of 15 to 20 percent of cancers having a link to infectious agents may be too conservative.There are suggestions that pathogens may also underlie some forms of prostate, colorectal and lung cancers.
  
  And if that is so, he added, the search for targeted anti-infectives and vaccines becomes evermore crucial.

• 
  www.nypcancerprevention.com/issue/3/consumer/fro_edi.ht - [Cached Version]
  Published on: 4/1/2004    Last Visited: 3/13/2008  

  Andrew J. Dannenberg, MD (left) and Alfred I. Neugut, MD, PhD
  ...
  Andrew J. Dannenberg, MD

• 
  www.todaysseniorsnetwork.com/cancer_infection.htm - [Cached Version]
  Published on: 11/11/2005    Last Visited: 10/6/2008  

  "I believe that, conservatively, 15 to 20 percent of all cancer is caused by infections, however, the number could be larger -- maybe double," says Dr. Andrew J. Dannenberg, director of the Cancer Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and Henry R. Erle, M.D.-Roberts Family Professor of Medicine at Weill Cornell Medical College in New York City.
  ...
  During a speech at the American Association for Cancer Research's (AACR) Sixth Annual International Conference Frontiers in Cancer Prevention Research, on December 5, 6:00 p.m. EST, at the Philadelphia Marriot Downtown, Dr. Dannenberg, who is also the meeting's program committee chairperson, will highlight the link between chronic infection, inflammation and cancer as an opportunity to reduce the global cancer burden.

• 
  www.nursingcenter.com/prodev/ce_article.asp?tid=792842 - [Cached Version]
  Published on: 5/1/2008    Last Visited: 9/23/2008  

  Finding ways to interrupt this pathway in a manner that causes few side effects is the ultimate goal of this research," explains the study's senior author Dr. Andrew Dannenberg, Director of the newly established Cancer Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, and the Henry R. Erle, M.D.-Roberts Family Professor of Medicine at Weill Cornell Medical College.
  ...
  In 2006, researchers led by Dr. Dannenberg discovered that cyclooxygenase (COX) protein-derived prostaglandin E2 (PGE2) could turn on the gene that expresses aromatase.More recently, the healthy form of the BRCA1 tumor-suppressor gene was found to quiet the aromatase gene—performing its duty in keeping breast cancer risk low.
  
  "Maintaining this BRCA1-aromatase relationship in a healthy balance may help to keep patients free of hormone-dependent breast cancer," Dr. Dannenberg explains.
  
  Studies have shown that use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) can also dampen PGE2 production and aromatase activity.COX-2 inhibitors (which included Vioxx and Celebrex) may do the same.However, these drugs also suppress a prostanoid that helps protect the heart, and in 2004 Vioxx was withdrawn from the market due to an excess of cardiovascular events noted in long-term users.
  
  "So, we are always looking for other points in the prostaglandin—aromatase—estrogen pathway that can shield women from breast cancer without raising risks in other areas," Dr. Dannenberg says.
  
  That's one of the reasons the results of the new study are intriguing.
  ...
  "Pinpointing the role of these receptors is like adding two important new parts to the tumor's 'instruction kit.' You have to understand all the players involved if you hope to uncover weaknesses to fight or prevent the disease," Dannenberg says.

• 
  www.cancerprevention.org/research/dannenberg.cfm.htm - [Cached Version]
  Published on: 12/7/2005    Last Visited: 8/8/2007  

  Dr. Andrew DannenbergCancer Research and Prevention Foundation - Profiles: Dr. Andrew Dannenberg
  ...
  DR. ANDREW DANNENBERG
  ...
  In 1996, Dr. Andrew Dannenberg began his important research at Memorial Sloan-Kettering Cancer Center when he received a grant from the Cancer Research and Prevention Foundation.
  
  Today he is the director of cancer prevention at Weill Cornell Medical College in Manhattan, and the author of a critical study that suggests women who take aspirin regularly can lower their risk of developing the most common type of breast cancer.Aspirin is one type of non-steroidal anti-inflammatory drug.
  
  According to Dannenberg, his CRPF grant helped him in his career in research and was seminal to these latest findings on breast cancer prevention."CRPF lit a candle which ignited a bonfire," Dannenberg says, when describing the impact CRPF's grant had on his career and accomplishments.
  ...
  Dannenberg has called Mestre's fellowship "a great investment" in the future of a promising scientist, and in the future of cancer prevention.
  
  Dr. Louise Howe, another CRPF-funded researcher at Strang Cancer Research Laboratory and Weill Medical College of Cornell University, collaborated with Dannenberg on research that examined commonly used non-steroidal anti-inflammatory drugs, such as celecoxib.
  ...
  All of this research conducted under Dannenberg's leadership has helped change the face of cancer chemoprevention.Young investigators like these have made a great contribution, Dannenberg says, "work that would not be possible without the Foundation's continued confidence and support."

• 
  www.biospace.com/news_story.aspx?NewsEntityId=80242 - [Cached Version]
  Published on: 12/5/2007    Last Visited: 12/12/2007  

  "I believe that, conservatively, 15 to 20 percent of all cancer is caused by infections, however, the number could be largerâ€"maybe double," says Dr. Andrew J. Dannenberg, director of the Cancer Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center and Henry R. Erle, M.D.-Roberts Family Professor of Medicine at Weill Cornell Medical College in New York City.

• 
  aap-online.org/member/10016/Andrew_Dannenberg - [Cached Version]
  Published on: 10/12/2008    Last Visited: 8/3/2008  

  Andrew DannenbergAssociation of American Physicans
  
  Association of American Physicians

• 
  hurtbyadoctor.com/2007_12_01_archive.html - [Cached Version]
  Published on: 12/1/2007    Last Visited: 3/22/2008  

  Dr. Andrew Dannenberg, director of the Cancer Center at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in Manhattan, estimates that pathogens underlie anywhere from 15 to 20 percent of cancers affecting people globally.
  
  Many of the infectious agents that can cause cancer are more problematic in poorer countries where vaccine technology is nonexistent and costs to purchase from abroad prohibitive.
  
  The World Health Organization has underscored that the lack of money and poor refrigeration capacities in many underdeveloped countries makes access to the HPV vaccine difficult."There are about 450,000 new cases of cervical cancer each year worldwide, and more than 200,000 deaths," Dannenberg said.
  ...
  If a significant number of lives are to be saved we need one that doesn't require refrigeration," Dannenberg said.
  
  "Currently, you have to give three vaccinations," for the HPV vaccine to be complete, he added.

Page:  1 2 3 4 5